In this interview, Rafael Fonseca, MD, of the Mayo Clinic, Phoenix, AZ, discusses how measurable residual disease (MRD) should be used in the treatment of multiple myeloma (MM), including how his practice uses MRD. This video was recorded at the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL.
Uses of MRD in patients with multiple myeloma
